Nektar Therapeutics (NKTR) Tops Q3 EPS by 185c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $66.69 +1.51%
Revenue Growth %: -7.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: -7.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of $1.85. Revenue for the quarter came in at $11.79 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- KeyBanc Upgrades Nucor (NUE) to Overweight
- Axis Capital Limited Upgrades Tata Technologies (TATATECH:IN) to Buy (1)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
